Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428500 · ClinicalTrials.gov registry record · Phase 1
QTX3046 in Patients With KRAS G12D Mutations
A Phase 1 study of Advanced Solid Tumor, sponsored by Quanta Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 5
- Study locations
NCT06428500: Active Phase 1 study of Advanced Solid Tumor, sponsored by Quanta Therapeutics.
NCT06428500 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Quanta Therapeutics. The registered enrollment target is 240 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06428500, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Quanta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Primary Outcome
Define as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3046
Study Locations (5)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC San Antonio - San Antonio
Michigan
- South Texas Accelerated Research Therapeutics, LLC Midwest - Grand Rapids
North Carolina
- Duke Cancer Center - Durham
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
What the registry record for NCT06428500 still lists
NCT06428500 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06428500 lists 5 locations in 4 states (Texas, Michigan, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06428500 about?
NCT06428500 is a clinical study titled "QTX3046 in Patients With KRAS G12D Mutations". Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06428500?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-05-30. Estimated completion is 2027-07-01.
What conditions does trial NCT06428500 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06428500?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3046 (DRUG).
Who is sponsoring clinical trial NCT06428500?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06428500 being conducted?
This trial has 5 study locations across Michigan, North Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06428500's enrollment target sits among peer trials
240 49th of 189 higher than 139 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI